Reviewing Immunocore (IMCR) & The Competition

Immunocore (NASDAQ:IMCR) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its rivals? We will compare Immunocore to related businesses based on the strength of its risk, institutional ownership, dividends, profitability, earnings, analyst recommendations and valuation.

Earnings & Valuation

This table compares Immunocore and its rivals top-line revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Immunocore	$430.77 million	-$35.51 million	-48.24
Immunocore Competitors	$742.03 million	$14.11 million	-15.42

Immunocore’s rivals have higher revenue and earnings than Immunocore. Immunocore is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Immunocore and its rivals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunocore	1	4	5	1	2.55
Immunocore Competitors	9839	15125	45459	1588	2.54

Immunocore presently has a consensus target price of $55.86, indicating a potential upside of 78.14%. As a group, “Biotechnology” companies have a potential upside of 99.26%. Given Immunocore’s rivals higher probable upside, analysts plainly believe Immunocore has less favorable growth aspects than its rivals.

Risk and Volatility

Immunocore has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Immunocore’s rivals have a beta of 1.10, indicating that their average stock price is 10% more volatile than the S&P 500.

Insider & Institutional Ownership

84.5% of Immunocore shares are held by institutional investors. Comparatively, 47.9% of shares of all “Biotechnology” companies are held by institutional investors. 10.1% of Immunocore shares are held by insiders. Comparatively, 13.0% of shares of all “Biotechnology” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Immunocore and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Immunocore	-7.48%	-8.07%	-2.96%
Immunocore Competitors	-12,346.73%	-197.60%	-30.56%

Summary

Immunocore rivals beat Immunocore on 7 of the 13 factors compared.

About Immunocore

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company’s product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.